+Follow
PoptartBob
No personal profile
2
Follow
3
Followers
0
Topic
0
Badge
Posts
Hot
PoptartBob
2022-07-05
good
Sorry, the original content has been removed
PoptartBob
2022-06-30
great one
Pfizer Files for Full FDA Approval for COVID-19 Antiviral
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3575758612828517","uuid":"3575758612828517","gmtCreate":1612742167507,"gmtModify":1612776955486,"name":"PoptartBob","pinyin":"poptartbob","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/10ff2a5007f83b4e55eb5a9ab7cbfbd0","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":2,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.82%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.90%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9070137715,"gmtCreate":1657028664737,"gmtModify":1676535934329,"author":{"id":"3575758612828517","authorId":"3575758612828517","name":"PoptartBob","avatar":"https://static.tigerbbs.com/10ff2a5007f83b4e55eb5a9ab7cbfbd0","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575758612828517","authorIdStr":"3575758612828517"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/9070137715","repostId":"1181680979","repostType":4,"isVote":1,"tweetType":1,"viewCount":504,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4113904591642392","authorId":"4113904591642392","name":"LMSunshine","avatar":"https://community-static.tradeup.com/news/0ad636f2490d8428fcee9da6d669e46c","crmLevel":1,"crmLevelSwitch":0,"idStr":"4113904591642392","authorIdStr":"4113904591642392"},"content":"Are you new to Tiger? If yes,🥳welcome to the Tiger Community.I can’t follow more people as my app keeps crashing.If you follow me,I can check your homepage regularly & help to like your post too!","text":"Are you new to Tiger? If yes,🥳welcome to the Tiger Community.I can’t follow more people as my app keeps crashing.If you follow me,I can check your homepage regularly & help to like your post too!","html":"Are you new to Tiger? If yes,🥳welcome to the Tiger Community.I can’t follow more people as my app keeps crashing.If you follow me,I can check your homepage regularly & help to like your post too!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9045807743,"gmtCreate":1656590005082,"gmtModify":1676535858917,"author":{"id":"3575758612828517","authorId":"3575758612828517","name":"PoptartBob","avatar":"https://static.tigerbbs.com/10ff2a5007f83b4e55eb5a9ab7cbfbd0","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575758612828517","authorIdStr":"3575758612828517"},"themes":[],"htmlText":"great one","listText":"great one","text":"great one","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9045807743","repostId":"2247475886","repostType":4,"repost":{"id":"2247475886","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1656587274,"share":"https://ttm.financial/m/news/2247475886?lang=&edition=fundamental","pubTime":"2022-06-30 19:07","market":"us","language":"en","title":"Pfizer Files for Full FDA Approval for COVID-19 Antiviral","url":"https://stock-news.laohu8.com/highlight/detail?id=2247475886","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 tr","content":"<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>"Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status," said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&P 500 has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Files for Full FDA Approval for COVID-19 Antiviral</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Files for Full FDA Approval for COVID-19 Antiviral\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-06-30 19:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>"Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status," said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&P 500 has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4570":"地缘局势概念股","BK4139":"生物科技","NGD":"New Gold","PFE":"辉瑞","BK4568":"美国抗疫概念","BK4581":"高盛持仓","BK4550":"红杉资本持仓","BK4017":"黄金","BK4007":"制药","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BNTX":"BioNTech SE"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2247475886","content_text":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.PAXLOVID has previously been granted Emergency Use Authorization $(EUA.UK)$ for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.\"Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,\" said Pfizer Chief Executive Albert Bourla.The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&P 500 has climbed 19.9%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9070137715,"gmtCreate":1657028664737,"gmtModify":1676535934329,"author":{"id":"3575758612828517","authorId":"3575758612828517","name":"PoptartBob","avatar":"https://static.tigerbbs.com/10ff2a5007f83b4e55eb5a9ab7cbfbd0","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575758612828517","idStr":"3575758612828517"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/9070137715","repostId":"1181680979","repostType":4,"repost":{"id":"1181680979","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":1,"media_name":"Dow Jones","id":"1012688067","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1657024170,"share":"https://ttm.financial/m/news/1181680979?lang=&edition=fundamental","pubTime":"2022-07-05 20:29","market":"fut","language":"en","title":"Gold Weakens As Dollar Climbs to 22-Year High Vs. Euro","url":"https://stock-news.laohu8.com/highlight/detail?id=1181680979","media":"Dow Jones","summary":"Gold prices weakened again on Thursday, breaking below $1,800 per ounce, as the U.S. dollar climbed ","content":"<html><head></head><body><p>Gold prices weakened again on Thursday, breaking below $1,800 per ounce, as the U.S. dollar climbed to a new 22-year high against the euro.</p><h3>Price action</h3><ul><li>Gold prices for August delivery shed $4, or 0.2%, to $1,797.</li><li>Silver prices for September delivery were flat at $19.70 per ounce.</li><li>Palladium prices for September delivery were off $37.10, or 1.9%, to $1,901 per ounce.</li><li>Platinum prices for October delivery dropped $15.50, or 1.8%, at $855.50 per ounce.</li><li>Copper prices for September delivery were down 13 cents or 3.6%, to $3.47 per pound.</li></ul><h3>What analysts are saying</h3><p>Naeem Aslam, chief market analyst at AvaTrade, blamed the dollar’s moves for driving price action in gold.</p><p>The greenback EURUSD traded at a new 22-year high against the euro on Tuesday, with one dollar buying roughly 1.03 euros.</p><p>Jim Wyckoff, senior analyst at Kitco.com, said technical indicators in recent trade for both gold and silver are now “fully bearish.”</p><p>“The metals are feeling the pressure of a stronger U.S. dollar index that notched a 20-year high overnight,” Wyckoff added.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gold Weakens As Dollar Climbs to 22-Year High Vs. Euro</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGold Weakens As Dollar Climbs to 22-Year High Vs. Euro\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1012688067\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-07-05 20:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Gold prices weakened again on Thursday, breaking below $1,800 per ounce, as the U.S. dollar climbed to a new 22-year high against the euro.</p><h3>Price action</h3><ul><li>Gold prices for August delivery shed $4, or 0.2%, to $1,797.</li><li>Silver prices for September delivery were flat at $19.70 per ounce.</li><li>Palladium prices for September delivery were off $37.10, or 1.9%, to $1,901 per ounce.</li><li>Platinum prices for October delivery dropped $15.50, or 1.8%, at $855.50 per ounce.</li><li>Copper prices for September delivery were down 13 cents or 3.6%, to $3.47 per pound.</li></ul><h3>What analysts are saying</h3><p>Naeem Aslam, chief market analyst at AvaTrade, blamed the dollar’s moves for driving price action in gold.</p><p>The greenback EURUSD traded at a new 22-year high against the euro on Tuesday, with one dollar buying roughly 1.03 euros.</p><p>Jim Wyckoff, senior analyst at Kitco.com, said technical indicators in recent trade for both gold and silver are now “fully bearish.”</p><p>“The metals are feeling the pressure of a stronger U.S. dollar index that notched a 20-year high overnight,” Wyckoff added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181680979","content_text":"Gold prices weakened again on Thursday, breaking below $1,800 per ounce, as the U.S. dollar climbed to a new 22-year high against the euro.Price actionGold prices for August delivery shed $4, or 0.2%, to $1,797.Silver prices for September delivery were flat at $19.70 per ounce.Palladium prices for September delivery were off $37.10, or 1.9%, to $1,901 per ounce.Platinum prices for October delivery dropped $15.50, or 1.8%, at $855.50 per ounce.Copper prices for September delivery were down 13 cents or 3.6%, to $3.47 per pound.What analysts are sayingNaeem Aslam, chief market analyst at AvaTrade, blamed the dollar’s moves for driving price action in gold.The greenback EURUSD traded at a new 22-year high against the euro on Tuesday, with one dollar buying roughly 1.03 euros.Jim Wyckoff, senior analyst at Kitco.com, said technical indicators in recent trade for both gold and silver are now “fully bearish.”“The metals are feeling the pressure of a stronger U.S. dollar index that notched a 20-year high overnight,” Wyckoff added.","news_type":1},"isVote":1,"tweetType":1,"viewCount":504,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4113904591642392","authorId":"4113904591642392","name":"LMSunshine","avatar":"https://community-static.tradeup.com/news/0ad636f2490d8428fcee9da6d669e46c","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4113904591642392","idStr":"4113904591642392"},"content":"Are you new to Tiger? If yes,🥳welcome to the Tiger Community.I can’t follow more people as my app keeps crashing.If you follow me,I can check your homepage regularly & help to like your post too!","text":"Are you new to Tiger? If yes,🥳welcome to the Tiger Community.I can’t follow more people as my app keeps crashing.If you follow me,I can check your homepage regularly & help to like your post too!","html":"Are you new to Tiger? If yes,🥳welcome to the Tiger Community.I can’t follow more people as my app keeps crashing.If you follow me,I can check your homepage regularly & help to like your post too!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9045807743,"gmtCreate":1656590005082,"gmtModify":1676535858917,"author":{"id":"3575758612828517","authorId":"3575758612828517","name":"PoptartBob","avatar":"https://static.tigerbbs.com/10ff2a5007f83b4e55eb5a9ab7cbfbd0","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575758612828517","idStr":"3575758612828517"},"themes":[],"htmlText":"great one","listText":"great one","text":"great one","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9045807743","repostId":"2247475886","repostType":4,"isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
